Clinical Trials
KalVista begins phase 1 study of KVD818 in hereditary...
KalVista Pharmaceuticals announced the dosing of the first subject in a first-in-human clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally delivered KVD818...
Clinical Trials
Alzheimer’s drug shows promise for patients in phase III...
At the Alzheimer's Association International Conference 2016 (AAIC 2016), held in Toronto, Canada, researchers reveal how a drug called LMTX shows promise for halting the...
Clinical Trials
AstraZeneca Provides Update on Phase III Trial of Selumetinib...
AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients...
Clinical Trials
Antibe Therapeutics Announces Successful Phase 2 Trial Of ATB-346...
Antibe Therapeutics Inc. is pleased to announce the successful completion of its phase 2 clinical trial of ATB-346 in osteoarthritis (“OA”). Twelve patients with OA...
Clinical Trials
ClinicalRM And Mapp Biopharmaceutical Combine Efforts To Continue The...
ClinicalRM will again deploy its boots-on-the-ground approach to fighting Ebola Virus Disease (EVD) with an expanded access protocol for ZMappTM, an investigational treatment for EVD,...
Clinical Trials
Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical...
Inovio Pharmaceuticals, Inc announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition...
Clinical Trials
Positive VIMPAT monotherapy Phase III trial results presented at...
Trial further highlights UCB’s longstanding commitment to enhancing value for people living with epilepsy Data submitted to EMA earlier this year to extend the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.